Accessibility Menu
Microbix Biosystems logo

Microbix Biosystems(OTC) MBXBF

Market Cap$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-26%
5 Year-56%
1 Year+3%
1 Month+5%
$0.23
+0.00%
+0.00Today
Microbix Biosystems last closing stock price
MetricPriceDate
Last closeUSD 0.222026-07-28
Microbix Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.04%USD 0.212026-07-16
1 month+4.76%USD 0.212026-06-25
3 month+21.08%USD 0.182026-04-29
Year to date+26.36%USD 0.172025-12-30
1 year+2.67%USD 0.212025-07-28
3 year-8.33%USD 0.242023-07-28
5 year-55.7%USD 0.502021-07-28
Since inception-26.3%USD 0.302012-06-08

Microbix Biosystems Financials at a Glance

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$15.41M

Net Income (TTM)

-CA$4.41M

EPS (TTM)

-$0.03

P/E Ratio

-8.63

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Price

$0.23

Volume

1,300

Open

$0.23

Previous Close

$0.23

Daily Range

$0.23 - $0.23

52-Week Range

$0.15 - $0.23

Estimated Earnings Date

Dec 17, 2026

MBXBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microbix Biosystems

Microbix Biosystems Inc. is a life sciences company focused on developing and marketing innovative biological products that enhance human health. The company specializes in producing essential biological reagents for the diagnostics industry, including antigens and proprietary Quality Assessment and Proficiency (QAP) products.

Products and Services
  • Biological reagents for diagnostics, including antigens for immunoassays
  • Quality Assessment and Proficiency (QAP) products for clinical laboratories
  • Specialized products like DxTM (viral transport medium) and Kinlytic Urokinase
Growth Outlook
  • Expansion into international markets enhances revenue potential
  • Increasing demand for diagnostic products supports long-term growth
  • Investment in R&D aims to innovate and diversify product offerings
Financial Highlights
  • Recent quarterly revenue of CAD 3.39 million shows a solid market presence
  • Trailing twelve months (TTM) gross profit margin stands at 42.49%
  • Current ratio of 5.35 indicates strong liquidity and financial health
Microbix Biosystems Inc. operates in the biotechnology sector, primarily serving the diagnostics industry. The company has established a reputation for quality and innovation, particularly with its QAP products, which are essential for laboratory proficiency testing. The recent quarterly revenue reflects a robust demand for its offerings, while the gross profit margin indicates effective cost management. The growth outlook remains positive, driven by expanding market opportunities and a commitment to research and development. The company's strong liquidity position, as evidenced by a current ratio of 5.35, suggests it is well-equipped to navigate challenges and capitalize on growth opportunities. Overall, Microbix Biosystems Inc. presents a compelling case for potential investors interested in the biotechnology sector.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Cameron L. Groome

Website

microbix.com

Headquarters

Mississauga, ON L4Z 1P3, CA

MBXBF Financials

Key Financial Metrics (TTM)

Gross Margin

45.90%

Operating Margin

-27.69%

Net Income Margin

-31.72%

Return on Equity

-18.83%

Return on Capital

-4.39%

Return on Assets

-14.34%

Earnings Yield

-11.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

137.50M

Volume

1.30K

Avg. Volume

5.20K

Financials (TTM)

Gross Profit

CA$7.07M

Operating Income

-CA$4.40M

EBITDA

-CA$2.48M

Operating Cash Flow

-CA$3.29M

Capital Expenditure

-CA$595.84K

Free Cash Flow

-CA$3.89M

Cash & ST Invst.

CA$7.16M

Total Debt

CA$6.72M

Microbix Biosystems Performance Analysis

Microbix Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30CAD 14,931,1281.6%
20232023-09-30CAD 12,244,253-18.0%
20242024-09-30CAD 18,661,00252.4%
20252025-09-30CAD 13,292,966-28.8%
Microbix Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-308.0%
Q12025-12-3112.4%
Q22026-03-31-19.7%
Q32026-06-3019.9%
Microbix Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30CAD 0.01-51.9%
20232023-09-30CAD -0.00N/A
20242024-09-30CAD 0.02N/A
20252025-09-30CAD -0.01N/A
Microbix Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-3011.7%
Q12025-12-3120.8%
Q22026-03-31-22.6%
Q32026-06-3041.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$4.06M

+17.0%

Gross Profit

CA$2.19M

+54.8%

Gross Margin

53.92%

N/A

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$302.50K

N/A

Employees

100

N/A

Net Income

-CA$807.11K

+50.9%

EBITDA

-CA$186.54K

+80.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$7.16M

-40.8%

Total Debt

CA$6.72M

+4.9%

Accounts Receivable

CA$2.58M

+7.7%

Inventory

CA$10.57M

+19.3%

Long Term Debt

CA$6.49M

+4.9%

Short Term Debt

CA$226.70K

+6.5%

Return on Assets

-14.34%

N/A

Return on Invested Capital

-13.76%

N/A

Free Cash Flow

-CA$514.90K

+75.7%

Operating Cash Flow

-CA$467.02K

+75.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DTCFFDefence Therapeutics Inc.
$0.34+2.08%
RVXCFResverlogix Corp.
$0.08-4.88%
PVCTProvectus Biopharmaceuticals, Inc.
$0.06+3.31%
CLYYFCelyad Oncology S.A.
$0.28+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About MBXBF

What is the current price of Microbix Biosystems?

Microbix Biosystems is trading at $0.23 per share.

What is the 52-week range for Microbix Biosystems?

Over the past 52 weeks, Microbix Biosystems has traded between $0.15 and $0.23.

How much debt does Microbix Biosystems have?

As of the most recent reporting period, Microbix Biosystems reported total debt of CA$4.74M.

How much cash does Microbix Biosystems have on hand?

Microbix Biosystems reported CA$5.05M in cash and cash equivalents in its most recent financial results.

What is Microbix Biosystems’s dividend yield?

Microbix Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services